

Figure 1: Incidence of Resistance in Nucleoside Naive Patients




Figure 2: Incidence of Resistance in Lamivudine Refractory patients





Figure 3: Management of HBV drug resistance



* Not yet approved for HBV therapy

Table 1: Results of in vitro cross-resistance analysis

	Resistance mutation		Resistance mutation	Resistance mutation	Resistance mutation
	L180M + M204V	M204I	N236T	A181V	S202G/I* M250I*
Drugs with reduced activity	Lamivudine Entecavir Emtricitabine Clevudine Telbivudine Elvucitabine	Lamivudine Telbivudine Emtricitabine Entecavir	Adefovir Tenofovir	Adefovir Lamivudine	Entecavir Lamivudine Telbivudine
Drugs that remain active	Adefovir Tenofovir		Lamivudine Emtricitabine Entecavir Telbivudine	Tenofovir Entecavir	Adefovir Tenofovir

* : in the presence of primary resistance mutations (L180M + M204V)